Dipeptide-2

Dipeptide-2 is a synthetic dipeptide composed of valine and tryptophan (Val-Trp). It is a cosmetic ingredient with INCI database listing, marketed primarily for periorbital applications. The compound is a component of the Sederma raw material complex Eyeliss, which combines Dipeptide-2 with hesperidin methyl chalcone and the tetrapeptide palmitoyl-tetrapeptide-7 (Pal-GQPR).

The compound was developed in the cosmetic-industry pipeline rather than from pharmaceutical research. Its functional claim is specifically directed at under-eye puffiness, which is associated with several mechanisms: dermal microvascular fragility, impaired lymphatic drainage, age-related fat herniation, and edema secondary to sleep deprivation or salt intake. The cosmetic positioning targets the lymphatic and microvascular components rather than structural anatomy.

The evidence base is supplier-generated and finished-product focused. Sederma technical documentation describes user studies of Eyeliss-containing formulations showing measurable reductions in periorbital puffiness over several weeks of twice-daily application. Standalone Dipeptide-2 efficacy has not been isolated in publicly available controlled studies.

The Evidence

Supplier studies describe Eyeliss-containing cream formulations reducing periorbital bag depth and puffiness scores in panel studies of healthy women aged 35 to 65. Study durations have typically been 28 to 56 days with twice-daily application. Methods used include three-dimensional skin imaging, panel-evaluator scoring, and consumer self-assessment.

Mechanism work in cell culture has examined Dipeptide-2 effects on endothelial cell function and lymphatic vessel formation markers. The published data is limited and largely directed at supporting the marketing positioning rather than answering broader pharmacological questions.

Independent confirmation outside the cosmetic-industry literature is sparse. PubMed indexing for Dipeptide-2 specific work returns few primary research papers. The compound's evidence base sits firmly in the cosmetic-ingredient category rather than in the clinical-trial category that applies to compounds with therapeutic indications.

Regulatory and Legal Status

FDA. No drug approval. Permitted as a cosmetic ingredient.

EMA. Similar cosmetic-ingredient status.

INCI. Listed as Dipeptide-2.

Compounding. Not on the FDA bulk drug substances list.

WADA. Not on the 2026 Prohibited List.

The proposed mechanism centers on microvascular and lymphatic effects in the periorbital region.

Lymphatic drainage support. Dipeptide-2 is claimed to support lymphatic vessel function and improve drainage of interstitial fluid from periorbital tissue. The proposed mechanism involves effects on lymphatic endothelial cell function, possibly through modulation of cell-junction proteins or contractile activity in collecting lymphatic vessels.

Capillary stabilization. The dipeptide is reported to reduce capillary permeability in cell-culture models, which would translate to reduced extravasation of fluid and proteins into periorbital interstitial space. Reduced extravasation is mechanistically linked to reduced puffiness.

Combined formulation effects. In Eyeliss, Dipeptide-2 is combined with hesperidin methyl chalcone (a citrus-derived flavonoid with established capillary-strengthening claims) and Pal-GQPR (a palmitoylated tetrapeptide claimed to improve dermal firmness). The marketing positioning treats the combination as synergistic, targeting the puffiness phenomenon through multiple complementary pathways. Whether Dipeptide-2 contributes the dominant effect or operates additively with the other components has not been isolated.

Pharmacokinetics. Topical Val-Trp absorption through intact skin is limited by the dipeptide's hydrophilicity and the skin barrier function. Cosmetic-formulation penetration enhancers (propylene glycol, glycerin, surfactants) are used to improve dermal delivery. Systemic absorption from periorbital topical application at cosmetic concentrations is minimal.

Effects reported in cosmetic-supplier and consumer studies:

• Reduction in periorbital puffiness over 4 to 8 weeks of twice-daily application
• Improvement in under-eye skin smoothness scores
• Possible reduction in dark circles in some users (likely through reduced fluid pooling and shadow effects rather than pigmentation change)
• Generally well-tolerated topical application in periorbital area

Consumer reports from finished-product use describe variable individual responses. Improvement in puffiness is typically modest and gradual rather than dramatic, with the most consistent benefit reported in users whose puffiness reflects fluid accumulation rather than structural fat herniation. Users with anatomical periorbital changes (age-related lid laxity, true fat pad herniation) typically report less benefit, since these are not addressable by topical peptide intervention.

Topical cosmetic concentrations for Dipeptide-2 in marketed products are typically expressed as the percentage of the Eyeliss raw material complex in finished formulation, ranging from 1 to 3 percent. The Dipeptide-2 active ingredient is present at a lower concentration within the complex, with the specific amount considered proprietary by the supplier.

Application frequency is typically twice daily, morning and evening, applied gently to clean periorbital skin. Effective absorption depth and tissue concentration at standard cosmetic doses have not been comprehensively characterized.

No injectable, oral, or systemic dosing protocol for Dipeptide-2 exists or is supported by safety data. The compound is restricted to topical cosmetic use.

Topical Dipeptide-2 at cosmetic concentrations has an acceptable safety record in marketed periorbital formulations. Reported reactions:

• Mild local irritation at higher concentrations or in sensitive periorbital skin
• Rare contact dermatitis
• Possible eye irritation if product contacts the ocular surface
• Possible interactions with other actives in periorbital formulation (retinoids, alpha-hydroxy acids)

Safety considerations specific to higher-concentration use or non-topical routes:

• Effects in pregnancy and breastfeeding have not been formally evaluated; cosmetic use is generally considered acceptable
• The periorbital area is anatomically sensitive; application should avoid the ocular surface
• Long-term safety of chronic daily application over many years has not been formally characterized

Drug-drug interaction data with topical hair-loss medications, prescription periorbital products, or systemic medications has not been studied. The minimal systemic absorption at cosmetic doses limits clinically significant interaction risk.

Dipeptide-2 is most commonly used in periorbital cosmetic formulations rather than as a standalone active. The primary commercial vehicle is the Sederma Eyeliss complex, which includes Dipeptide-2 alongside hesperidin methyl chalcone and Pal-GQPR.

For broader periorbital and anti-aging cosmetic stacks, Dipeptide-2 is combined with:

• Matrixyl and Matrixyl 3000 for collagen-stimulation claims
• Argireline for expression-line softening
• SNAP-8 as an extended Argireline analog
• Caffeine for additional vasoconstrictive and depuffing effects
• Hyaluronic acid for hydration

The cosmetic stacking landscape is large, and most marketed eye products combine 3 to 10 active ingredients. Head-to-head comparative evidence for specific peptide combinations is minimal. Most cosmetic decisions are guided by marketing claims, formulation vehicle quality, and individual response rather than by trial data.

For users with periorbital concerns, the relevant comparison includes non-peptide approaches: cold compresses for acute puffiness, sleep and hydration optimization, salt intake moderation, dermatologist-supervised treatments (vascular laser for dark circles, fillers for tear trough deficiency, surgical blepharoplasty for true fat pad herniation). Topical Dipeptide-2 sits at the mildest end of the intervention spectrum.

For informational and educational purposes only. Not medical advice. Not for human consumption unless prescribed by a licensed physician for an FDA-approved indication. Consult a qualified healthcare provider before using any peptide or pharmaceutical product.